v3.25.1
Condensed Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (5,896,839) $ (3,599,510)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 77,682 69,983
Amortization 7,171 1,245
Amortization of right-of-use assets 132,207 152,664
Accounts receivable reserve (5,000) 1,000
Loss on property and equipment dispositions 43,507 0
Share-based compensation expense 367,237 77,585
Amortization of debt issuance costs and discount 356,699 258,802
Changes in operating assets and liabilities:    
Accounts receivable 259,775 (22,623)
Inventory (815,865) (304,179)
Prepaid and other assets (53,523) (187,359)
Accounts payable 890,678 (137,753)
Accrued expenses 19,239 (792,239)
Lease liabilities (133,076) (44,745)
Other liabilities (15,106) (40,995)
Net cash used in operating activities (4,765,214) (4,568,124)
Cash flows from investing activities:    
Acquisition of patents 0 (25,603)
Purchases of property and equipment (96,605) (64,557)
Net cash used in investing activities (96,605) (90,160)
Cash flows from financing activities:    
Proceeds from at-the-market sales of common stock 5,392,027 802,242
Issuance costs for at-the-market sales of common stock (161,761) (24,067)
Net cash provided by financing activities 5,230,266 778,175
Net change in cash and cash equivalents 368,447 (3,880,109)
Cash and cash equivalents:    
Beginning of period 3,451,761 21,716,077
End of period 3,820,208 17,835,968
Non-cash investing and financing activities:    
Property and equipment costs included in accounts payable and accrued expense 22,072 108,304
Acquisition of patents included in accounts payable 0 8,757
Deferred offering costs reclassified to additional paid-in-capital $ 8,369 $ 1,245